TY - JOUR AU - Szekanecz, Zoltán AU - Szamosi, Szilvia AU - Benkő, Szilvia AU - Szűcs, Gabriella TI - Monogénesen öröklődő és szerzett autoinflammatoricus betegségek JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 18 SP - 683 EP - 697 PG - 15 SN - 0030-6002 UR - https://m2.mtmt.hu/api/publication/34797501 ID - 34797501 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Major, Tamás AU - Nagy, Gábor AU - Szabó, Judit AU - Mózes, Huba AU - Szűcs, Gabriella AU - Szekanecz, Zoltán AU - Szamosi, Szilvia TI - Granulomatosis with polyangiitis or its mimic? A case report JF - JOURNAL OF INTERNATIONAL MEDICAL RESEARCH J2 - J INT MED RES VL - 52 PY - 2024 IS - 4 SP - 1 EP - 8 PG - 8 SN - 0300-0605 DO - 10.1177/03000605241237876 UR - https://m2.mtmt.hu/api/publication/34788385 ID - 34788385 AB - Differentiation between granulomatosis with polyangiitis (GPA) limited to the upper airways and cocaine-induced midline destructive lesion (CIMDL) may be particularly difficult because of their common histopathologic features and antineutrophil cytoplasmic antibody (ANCA) profiles. We herein present a case involving a young woman with an initial diagnosis of GPA based on upper and lower airway manifestations and constitutional symptoms, histopathologic evidence of granulomas, a positive cytoplasmic ANCA indirect immunofluorescent test result, and proteinase 3 positivity by enzyme-linked immunosorbent assay (ELISA). CIMDL was confirmed based on the appearance of a hard palate perforation, positivity for methylecgonine on urine toxicology, a positive perinuclear ANCA indirect immunofluorescent test result, and subsequent human neutrophil elastase (HNE) ANCA positivity by ELISA. Finally, based on the coexistence of CIMDL, constitutional symptoms, and lower airway manifestations, the diagnosis was modified to cocaine-induced GPA mimic. Urine toxicology for cocaine and HNE ELISA are indicated in young patients with GPA who develop limited airway disease to check for the presence of CIMDL and cocaine-/levamisole-induced ANCA-associated vasculitis. Continued abstinence from cocaine is the first-choice therapy for both CIMDL and cocaine-induced GPA mimic. LA - English DB - MTMT ER - TY - JOUR AU - Simon, Diána AU - Kacsándi, Dorottya AU - Karancsiné Pusztai, Anita AU - Soós, Boglárka AU - Végh, Edit AU - Kerekes, György AU - Czókolyová, Monika AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Prohászka, Zoltán AU - Németh, Péter AU - Berki, Tímea AU - Szekanecz, Zoltán TI - Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 6 PG - 14 SN - 1661-6596 DO - 10.3390/ijms25063429 UR - https://m2.mtmt.hu/api/publication/34745209 ID - 34745209 N1 - * Megosztott szerzőség AB - Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (p < 0.05). We also found associations between anti-TOPO-F4 IgG and anti-Hsp60 IgG (p < 0.05). Baseline nAAb levels or nAAb level changes might determine changes in CRP, disease activity, FMD, PWV, and ccIMT over time (p < 0.05). The interplay between arthritis and inflammatory atherosclerosis, as well as the effects of anti-TNF biologics on these pathologies, might independently involve nAAbs. LA - English DB - MTMT ER - TY - JOUR AU - Kerekes, György AU - Bodoki, Levente AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Tajti, Gábor AU - Katkó, Mónika AU - Végh, Edit AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Horváth, Ágnes AU - Soós, B. AU - Szamosi, Szilvia AU - Hascsi, Z. AU - Harangi, Mariann AU - Panyi, György AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - AB0237 EFFECTS OF ONE-YEAR TOFACITINIB THERAPY ON ANGIOGENIC BIOMARKERS IN RHEUMATOID ARTHRITIS JF - ANNALS OF THE RHEUMATIC DISEASES J2 - ANN RHEUM DIS VL - 82 PY - 2023 IS - S1 SP - 1303 EP - 1303 PG - 1 SN - 0003-4967 DO - 10.1136/annrheumdis-2023-eular.2331 UR - https://m2.mtmt.hu/api/publication/34775337 ID - 34775337 LA - English DB - MTMT ER - TY - JOUR AU - Spiera, Robert F. AU - Unizony, Sebastian AU - Warrington, Kenneth J. AU - Sloane, Jennifer AU - Giannelou, Angeliki AU - Nivens, Michael C. AU - Akinlade, Bolanle AU - Wong, Wanling AU - Bhore, Rafia AU - Lin, Yong AU - Buttgereit, Frank AU - Devauchelle-Pensec, Valerie AU - Rubbert-Roth, Andrea AU - Yancopoulos, George D. AU - Marrache, Frederic AU - Patel, Naimish AU - Dasgupta, Bhaskar ED - Szűcs, Gabriella / Collaborator ED - Pethő, Zsófia / Collaborator ED - Soós, Boglárka / Collaborator ED - Szamosi, Szilvia / Collaborator ED - Végh, Edit / Collaborator TI - Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 389 PY - 2023 IS - 14 SP - 1263 EP - 1272 PG - 10 SN - 0028-4793 DO - 10.1056/NEJMoa2303452 UR - https://m2.mtmt.hu/api/publication/34391690 ID - 34391690 LA - English DB - MTMT ER - TY - JOUR AU - Szekanecz, Zoltán AU - Vokó, Zoltán AU - Surján, Orsolya AU - Rákóczi, Éva AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Szekanecz, Éva AU - Müller, Cecília AU - Kiss, Zoltán TI - Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 14 PY - 2023 PG - 8 SN - 1664-3224 DO - 10.3389/fimmu.2023.1247129 UR - https://m2.mtmt.hu/api/publication/34250233 ID - 34250233 N1 - * Megosztott szerzőség AB - Introduction In Hungary, the HUN-VE 3 study determined the comparative effectiveness of various primary and booster vaccination strategies during the Delta COVID-19 wave. That study included more than 8 million 18-100-year-old individuals from the beginning of the pandemic. Immunocompromised (IC) individuals have increased risk for COVID-19 and disease course might be more severe in them. In this study, we wished to estimate the risk of SARS-CoV-2 infection and COVID-19 related death in IC individuals compared to healthy ones and the effectiveness of the BNT162b2 vaccine by reassessing HUN-VE 3 data. Patients and methods Among the 8,087,988 individuals undergoing follow-up from the onset of the pandemic in the HUN-VE 3 cohort, we selected all the 263,116 patients with a diagnosis corresponding with IC and 6,128,518 controls from the second wave, before vaccinations started. The IC state was defined as two occurrences of corresponding ICD-10 codes in outpatient or inpatient claims data since 1 January, 2013. The control group included patients without chronic diseases. The data about vaccination, SARS-CoV-2 infection and COVID-19 related death were obtained from the National Public Health Center (NPHC) during the Delta wave. Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the National Public Health Center (NPHC). Results Out of the 263,116 IC patients 12,055 patients (4.58%) and out of the 6,128,518 healthy controls 202,163 (3.30%) acquired SARS-CoV-2 infection. Altogether 436 IC patients and 2141 healthy controls died in relation to COVID-19. The crude incidence rate ratio (IRR) of SARS-CoV-2 infection was 1.40 (95%CI: 1.37-1.42) comparing IC patients to healthy controls. The crude mortality rate ratio was 4.75 (95%CI: 4.28-5.27). With respect to SARS-CoV-2 infection, interestingly, the BNT162b2 vaccine was more effective in IC patients compared to controls. Primary vaccine effectiveness (VE) was higher in IC patients compared to controls and the booster restored VE after waning. VE regarding COVID-19 related death was less in IC patients compared to healthy individuals. Booster vaccination increased VE against COVID-19-related death in both IC patients and healthy controls. Conclusion There is increased risk of SARS-CoV-2 infection and COVID-19 related mortality in IC patient. Moreover, booster vaccination using BNT162b2 might restore impaired VE in these individuals. LA - English DB - MTMT ER - TY - JOUR AU - Kerekes, György AU - Czókolyová, Monika AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Tajti, Gábor AU - Katkó, Mónika AU - Végh, Edit AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Horváth, Ágnes AU - Soós, Boglárka AU - Szamosi, Szilvia AU - Hascsi, Zsolt AU - Harangi, Mariann AU - Hodosi, Katalin AU - Panyi, György AU - Seres, Tamás AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis JF - RHEUMATOLOGY (UNITED KINGDOM) J2 - RHEUMATOLOGY VL - 62 PY - 2023 IS - SI3 SP - SI304 EP - SI312 SN - 1462-0324 DO - 10.1093/rheumatology/kead502 UR - https://m2.mtmt.hu/api/publication/34215318 ID - 34215318 LA - English DB - MTMT ER - TY - JOUR AU - Kacsándi, Dorottya AU - Fagyas, Miklós AU - Horváth, Ágnes AU - Végh, Edit AU - Pusztai, Anita AU - Czókolyová, Monika AU - Soós, Boglárka AU - Szabó, Attila Ádám AU - Hamar, Attila AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Kerekes, György AU - Hodosi, Katalin AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Papp, Zoltán AU - Szekanecz, Zoltán TI - Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 10 PY - 2023 SN - 2296-858X DO - 10.3389/fmed.2023.1226760 UR - https://m2.mtmt.hu/api/publication/34185575 ID - 34185575 LA - English DB - MTMT ER - TY - JOUR AU - Végh, Edit AU - Bodnár, Nóra AU - Szamosi, Szilvia AU - Szántó, Sándor Zoltán AU - Szűcs, Gabriella AU - Szekanecz, Zoltán TI - Gyulladásos bélbetegségekhez társuló spondylarthritis JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 SP - 73 EP - 81 PG - 9 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34047238 ID - 34047238 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szamosi, Szilvia AU - Bodnár, Nóra AU - Bodoki, Levente AU - Gyetkó, Zsuzsanna AU - Horváth, Ágnes AU - Pethő, Zsófia AU - Tari, Dóra AU - Szekanecz, Zoltán AU - Szűcs, Gabriella TI - A szisztémás lupus erythematosus immunopatogenezise JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 15 PY - 2023 IS - 1 SP - 34 EP - 46 PG - 13 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/33724256 ID - 33724256 LA - Hungarian DB - MTMT ER -